Overview
This marketing authorisation for Fexeric has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Fexeric : EPAR - Summary for the public
English (EN) (252.54 KB - PDF)
български (BG) (314.37 KB - PDF)
español (ES) (250.12 KB - PDF)
čeština (CS) (302.38 KB - PDF)
dansk (DA) (248.78 KB - PDF)
Deutsch (DE) (252.04 KB - PDF)
eesti keel (ET) (245.44 KB - PDF)
ελληνικά (EL) (319.23 KB - PDF)
français (FR) (251.51 KB - PDF)
hrvatski (HR) (272.5 KB - PDF)
italiano (IT) (249.08 KB - PDF)
latviešu valoda (LV) (286.47 KB - PDF)
lietuvių kalba (LT) (276.98 KB - PDF)
magyar (HU) (293.07 KB - PDF)
Malti (MT) (301.08 KB - PDF)
Nederlands (NL) (249.38 KB - PDF)
polski (PL) (298.3 KB - PDF)
português (PT) (249.69 KB - PDF)
română (RO) (273.96 KB - PDF)
slovenčina (SK) (300.34 KB - PDF)
slovenščina (SL) (290.33 KB - PDF)
Suomi (FI) (248.57 KB - PDF)
svenska (SV) (246.33 KB - PDF)
Fexeric : EPAR - Risk-management-plan summary
English (EN) (259.25 KB - PDF)
Product information
Fexeric : EPAR - Product Information
English (EN) (463.01 KB - PDF)
български (BG) (937.09 KB - PDF)
español (ES) (462.93 KB - PDF)
čeština (CS) (787.3 KB - PDF)
dansk (DA) (465.89 KB - PDF)
Deutsch (DE) (490.13 KB - PDF)
eesti keel (ET) (468.75 KB - PDF)
ελληνικά (EL) (972.13 KB - PDF)
français (FR) (483.29 KB - PDF)
hrvatski (HR) (572.88 KB - PDF)
íslenska (IS) (471.06 KB - PDF)
italiano (IT) (476.59 KB - PDF)
latviešu valoda (LV) (785.64 KB - PDF)
lietuvių kalba (LT) (584.34 KB - PDF)
magyar (HU) (776.26 KB - PDF)
Malti (MT) (802.5 KB - PDF)
Nederlands (NL) (485.05 KB - PDF)
norsk (NO) (480.48 KB - PDF)
polski (PL) (793.89 KB - PDF)
português (PT) (461.27 KB - PDF)
română (RO) (588.89 KB - PDF)
slovenčina (SK) (770.04 KB - PDF)
slovenščina (SL) (728.68 KB - PDF)
Suomi (FI) (459.1 KB - PDF)
svenska (SV) (466.98 KB - PDF)
Latest procedure affecting product information: T/0015
09/09/2019
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Fexeric : EPAR - All Authorised presentations
English (EN) (178.18 KB - PDF)
български (BG) (210.72 KB - PDF)
español (ES) (180.58 KB - PDF)
čeština (CS) (201.02 KB - PDF)
dansk (DA) (180.26 KB - PDF)
Deutsch (DE) (180.23 KB - PDF)
eesti keel (ET) (180.39 KB - PDF)
ελληνικά (EL) (211.9 KB - PDF)
français (FR) (180.33 KB - PDF)
hrvatski (HR) (193.25 KB - PDF)
íslenska (IS) (181.64 KB - PDF)
italiano (IT) (180.4 KB - PDF)
latviešu valoda (LV) (205.72 KB - PDF)
lietuvių kalba (LT) (196.89 KB - PDF)
magyar (HU) (200.44 KB - PDF)
Malti (MT) (201.34 KB - PDF)
Nederlands (NL) (180.21 KB - PDF)
norsk (NO) (181.79 KB - PDF)
polski (PL) (195.46 KB - PDF)
português (PT) (180.35 KB - PDF)
română (RO) (195.44 KB - PDF)
slovenčina (SK) (201.5 KB - PDF)
slovenščina (SL) (193.66 KB - PDF)
Suomi (FI) (180.12 KB - PDF)
svenska (SV) (180.33 KB - PDF)
Product details
- Name of medicine
- Fexeric
- Active substance
- ferric citrate coordination complex
- International non-proprietary name (INN) or common name
- ferric citrate coordination complex
- Therapeutic area (MeSH)
- Hyperphosphatemia
- Renal Dialysis
- Anatomical therapeutic chemical (ATC) code
- V03AE
Therapeutic indication
Fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD).
Authorisation details
- EMA product number
- EMEA/H/C/003776
- Marketing authorisation holder
- Akebia Europe Limited
c/o Matheson
70 Sir John Rogerson’s Quay
Dublin 2
Ireland - Marketing authorisation issued
- 23/09/2015
- Lapse of marketing authorisation
- 13/01/2020
- Revision
- 2
Assessment history
Fexeric : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (320.19 KB - PDF)
Fexeric : EPAR - Public assessment report
English (EN) (3.31 MB - PDF)
CHMP summary of positive opinion for Fexeric
English (EN) (292.85 KB - PDF)
News on Fexeric
More information on Fexeric
Public statement on Fexeric: Cessation of validity of the marketing authorisation in the European Union
English (EN) (120.28 KB - PDF)